NCT07046494

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

CompletedPHASE2INTERVENTIONAL

Trial Details

Start: 2025-07-25Est. Completion: 2026-08-05

Enrollment target: 253 participants

Locations

Pillar Clinical Research - Little Rock, Little Rock, Arkansas, United States
Woodland Research Northwest, Rogers, Arkansas, United States
Inland Psychiatric Medical Group - Chino, Chino, California, United States
Synergy Clinical Research Center - San Diego, Lemon Grove, California, United States
Collaborative Neuroscience Research - Los Alamitos, Los Alamitos, California, United States
NRC Research Institute - Orange, Orange, California, United States
NeuroBehavioral Hospitals of the Palm Beaches - South, Boynton Beach, Florida, United States
United Research Institute, Hialeah, Florida, United States
CenExel - Hollywood, Hollywood, Florida, United States
Segal Trials - Miami Lakes Medical Research Early Phase, Inpatient & Outpatient Site, Miami Lakes, Florida, United States
Neuroscience Research Institute at Ambrosia, West Palm Beach, Florida, United States
CenExel - Decatur, Decatur, Georgia, United States
Pillar Clinical Research - Chicago, Chicago, Illinois, United States
CenExel - Gaithersburg, Gaithersburg, Maryland, United States

Bipolar Disorder Type I With Mania

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mani…

Glendale, United StatesEst. completion Jun 13, 2028

Mood DisordersSleep DisordersMigraine

This study will examine how depression, anxiety, and migraine run in families. It will help in defining the risk factors…

Bethesda, United States

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.